1. N17 Frequency of infliximab-induced skin lesions and their impact on quality of life in inflammatory bowel disease patients treated with infliximab. (25th January 2019) Authors: Bobnar Sekulic, C; Polanc, T; Koren, U; Kurent, T; Smrekar, N; Hanžel, J; Drobne, D; Novak, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P686 Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study. (25th January 2019) Authors: Kurent, T; Koren, U; Hanzel, J; Kozelj, M; Novak, G; Smrekar, N; Stabuc, B; Kecelj, N; Drobne, D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease. (30th January 2023) Authors: Pintar, S; Hanžel, J; Smrekar, N; Koželj, M; Drobne, D; Kurent, T; Štabuc, B; Novak, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE. (30th January 2023) Authors: Hanzel, J; Supovec, E; Smrekar, N; Koželj, M; Kurent, T; Štabuc, B; Novak, G; Drobne, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i850 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗